Topical formulations of cannabinoids and use thereof in the treatment of pain
Inventors
Wong, Hayes • Hossain, Sazzad • Cairns, Brian • Long, Karen Ann • Mancini, Alexandra
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12357604-B2
Publication Date
2025-07-15
Expiration Date
Abstract
Pharmaceutical compositions comprising one or more cannabinoids and a pharmaceutically acceptable carrier are disclosed. The compositions are in a form suitable for topical administration, and are useful in the treatment of pain. The cannabinoids suitable for use include cannabidiols, cannabinols, and various other naturally occurring and synthetic cannabinoids. The compositions may also further include anti-inflammatory agents, steroids, or terpenoids. In preferred embodiments, the cannabinoids incorporated in the compositions are cannabidiol (CBD) and cannabinol (CBN) while the carriers are selected from the group consisting of Labrasol™, Transcutol™, lecithin, lysolecithin, isopropyl palmitate, and isopropyl myristate.
Core Innovation
The disclosure describes a topical pharmaceutical composition for treating pain, comprising a therapeutically effective quantity of a mixture of one or more cannabidiols and cannabinol in a ratio of 5:1 µM. The therapeutically effective quantity induces no or substantially no psychoactive effect when administered by topical administration and is sufficient to reduce or reverse pain and/or central sensitization.
The composition includes at least one pharmaceutically acceptable carrier for topical administration, and the topical carrier comprises caprylocaproyl polyoxy-8 glycerides, poloxamer 407, lecithin, and isopropyl palmitate. The pharmaceutical composition is a topical formulation.
The patent further states that the composition increases mechanical threshold in peripheral nerve fibers and reduces or eliminates hyperalgesia and/or allodynia in the treated area. The described pain modalities include peripheral nerve pain, neuropathic pain, and muscle pain.
Claims Coverage
The document includes one independent claim, supported by dependent claims that refine the topical composition and treatment scope. The claim set centers on a topical pain-treatment composition with a 5:1 µM cannabidiols and cannabinol mixture, a no or substantially no psychoactive effect limitation, and a specified topical carrier.
Topical pain composition with 5:1 cannabidiols and cannabinol ratio
A pharmaceutical composition for treating pain comprising a therapeutically effective quantity of a mixture of one or more cannabidiols and cannabinol in a ratio of 5:1 µM, wherein the quantity induces no or substantially no psychoactive effect when administered by topical administration and is sufficient to reduce or reverse pain and/or central sensitization.
Topical formulation carrier with specified excipients
The pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier for topical administration, where the topical carrier comprises caprylocaproyl polyoxy-8 glycerides, poloxamer 407, lecithin, and isopropyl palmitate, and wherein the pharmaceutical composition is a topical formulation.
Across the independent claim, the core inventive structure is a topical pharmaceutical composition defined by a 5:1 µM cannabidiols and cannabinol mixture that induces no or substantially no psychoactive effect while reducing or reversing pain and/or central sensitization, together with a topical carrier comprising caprylocaproyl polyoxy-8 glycerides, poloxamer 407, lecithin, and isopropyl palmitate.
Stated Advantages
Induces no or substantially no psychoactive effect when administered by topical administration.
Reduces or reverses pain and/or central sensitization.
Increases mechanical threshold in peripheral nerve fibers.
Reduces or eliminates hyperalgesia and/or allodynia in the treated area.
Documented Applications
Topical treatment of pain in a mammalian subject in need thereof.
Wherein the pain is muscle pain.
Interested in licensing this patent?